141 related articles for article (PubMed ID: 11844638)
1. Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.
Andersen G; Christrup LL; Sjøgren P; Hansen SH; Jensen NH
J Pain Symptom Manage; 2002 Feb; 23(2):161-4. PubMed ID: 11844638
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
3. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
4. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.
Wolff T; Samuelsson H; Hedner T
Pain; 1996 Dec; 68(2-3):209-16. PubMed ID: 9121807
[TBL] [Abstract][Full Text] [Related]
5. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
[TBL] [Abstract][Full Text] [Related]
6. Randomized placebo-controlled trial of the activity of the morphine glucuronides.
Penson RT; Joel SP; Bakhshi K; Clark SJ; Langford RM; Slevin ML
Clin Pharmacol Ther; 2000 Dec; 68(6):667-76. PubMed ID: 11180027
[TBL] [Abstract][Full Text] [Related]
7. Morphine metabolites.
Christrup LL
Acta Anaesthesiol Scand; 1997 Jan; 41(1 Pt 2):116-22. PubMed ID: 9061094
[TBL] [Abstract][Full Text] [Related]
8. The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat.
Van Crugten JT; Somogyi AA; Nation RL; Reynolds G
Pain; 1997 Jun; 71(2):199-205. PubMed ID: 9211481
[TBL] [Abstract][Full Text] [Related]
9. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.
Goucke RC; Hackett PL; Ilett KF
Pain; 1994 Feb; 56(2):145-149. PubMed ID: 8008404
[TBL] [Abstract][Full Text] [Related]
10. Sex-specific differences in levels of morphine, morphine-3-glucuronide, and morphine antinociception in rats.
Baker L; Ratka A
Pain; 2002 Jan; 95(1-2):65-74. PubMed ID: 11790468
[TBL] [Abstract][Full Text] [Related]
11. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
Wolff T; Samuelsson H; Hedner T
Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
[TBL] [Abstract][Full Text] [Related]
13. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
Du X; Skopp G; Aderjan R
Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
[TBL] [Abstract][Full Text] [Related]
14. Morphine analgesia in cancer pain: role of the glucuronides.
Penson RT; Joel SP; Gloyne A; Clark S; Slevin ML
J Opioid Manag; 2005; 1(2):83-90. PubMed ID: 17319252
[TBL] [Abstract][Full Text] [Related]
15. Oral morphine in cancer pain: influences on morphine and metabolite concentration.
McQuay HJ; Carroll D; Faura CC; Gavaghan DJ; Hand CW; Moore RA
Clin Pharmacol Ther; 1990 Sep; 48(3):236-44. PubMed ID: 2401122
[TBL] [Abstract][Full Text] [Related]
16. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?
Faura CC; Olaso JM; Cabanes CG; Horga JF
Pain; 1996 Apr; 65(1):25-30. PubMed ID: 8826486
[TBL] [Abstract][Full Text] [Related]
17. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients.
Klepstad P; Borchgrevink PC; Dale O; Zahlsen K; Aamo T; Fayers P; Fougner B; Kaasa S
Palliat Med; 2003 Dec; 17(8):679-87. PubMed ID: 14694919
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.
Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ
Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
[TBL] [Abstract][Full Text] [Related]
20. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine.
van Dongen RT; Crul BJ; Koopman-Kimenai PM; Vree TB
Br J Clin Pharmacol; 1994 Sep; 38(3):271-3. PubMed ID: 7826830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
